4.2 Article

Rapid Expansion of KPC-2-Producing Klebsiella pneumoniae Isolates in Two Texas Hospitals due to Clonal Spread of ST258 and ST307 Lineages

期刊

MICROBIAL DRUG RESISTANCE
卷 19, 期 4, 页码 295-297

出版社

MARY ANN LIEBERT, INC
DOI: 10.1089/mdr.2012.0238

关键词

-

资金

  1. American Proficiency Institute (API)
  2. Anacor
  3. Astellas
  4. AstraZeneca
  5. Bayer
  6. Cempra
  7. Cerexa
  8. Contrafect
  9. Cubist
  10. Daiichi
  11. Dipexium
  12. Enanta
  13. Furiex
  14. GlaxoSmithKline
  15. Johnson & Johnson (Ortho McNeil)
  16. LegoChem Biosciences, Inc.
  17. Meiji Seika Kaisha
  18. Merck
  19. Nabriva
  20. Novartis
  21. Pfizer (Wyeth)
  22. Rempex
  23. Rib-X Pharmaceuticals
  24. Seachaid
  25. Shionogi
  26. Medicines Co.
  27. Theravance
  28. ThermoFisher

向作者/读者索取更多资源

During 2007 to 2010, 23 carbapenem-resistant Enterobacteriaceae strains were recovered in two hospitals in Texas among three institutions surveyed. Eighteen (2.0% overall) strains carried bla(KPC-2) and were collected in 2008 (3/150; 2.0%) and 2010 (15/289; 5.1%). Clonality was noted within hospitals and ten isolates belonged to ST258. All strains carried bla(KPC-2) on plasmids and 14 had this gene embedded in Tn4401a. Tn3 transposase was detected upstream of bla(KPC-2) in two isolates and another strain had two adjacent copies of bla(KPC). Surveillance in prior years shows sporadic detection of KPC-producers in Texas, however, a recent increase in carbapenem-resistant Enterobacteriaceae in this state was due to the spread of KPC-producing Klebsiella pneumoniae, including isolates from ST258.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据